Baras AS - Search Results

1

Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer.

Jiang G, Teramoto Y, Goto T, Mizushima T, Inoue S, Ide H, Nagata Y, Kashiwagi E, Baras AS, Netto GJ, Yang Z, Miyamoto H. Jiang G, et al. Among authors: baras as. Cancers (Basel). 2021 Feb 26;13(5):975. doi: 10.3390/cancers13050975. Cancers (Basel). 2021. PMID: 33652650 Free PMC article.

2

Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Michailidi C, Hayashi M, Datta S, Sen T, Zenner K, Oladeru O, Brait M, Izumchenko E, Baras A, VandenBussche C, Argos M, Bivalacqua TJ, Ahsan H, Hahn NM, Netto GJ, Sidransky D, Hoque MO. Michailidi C, et al. Cancer Prev Res (Phila). 2015 Mar;8(3):208-21. doi: 10.1158/1940-6207.CAPR-14-0251. Epub 2015 Jan 13. Cancer Prev Res (Phila). 2015. PMID: 25586904 Free PMC article.

3

Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.

Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu JJ, Kates M, Hoque MO, Berman D, Hahn NM, Eisenberger M, Netto GJ, Schoenberg MP, Bivalacqua TJ. Gandhi NM, et al. Urol Oncol. 2015 May;33(5):204.e1-7. doi: 10.1016/j.urolonc.2015.02.011. Epub 2015 Mar 23. Urol Oncol. 2015. PMID: 25814145 Free PMC article.

4

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.

Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, Schoenberg M, Hahn N, Hoque MO, Berman D, Bivalacqua TJ, Netto G. Baras AS, et al. PLoS One. 2015 Jul 31;10(7):e0131245. doi: 10.1371/journal.pone.0131245. eCollection 2015. PLoS One. 2015. PMID: 26230923 Free PMC article.

5

A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.

Park JC, Gandhi NM, Carducci MA, Eisenberger MA, Baras AS, Netto GJ, Liu JJ, Drake CG, Schoenberg MP, Bivalacqua TJ, Hahn NM. Park JC, et al. Among authors: baras as. J Urol. 2016 Apr;195(4 Pt 1):880-5. doi: 10.1016/j.juro.2015.11.024. Epub 2015 Nov 18. J Urol. 2016. PMID: 26598426

6

Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.

Kawahara T, Ide H, Kashiwagi E, Patterson JD, Inoue S, Shareef HK, Aljarah AK, Zheng Y, Baras AS, Miyamoto H. Kawahara T, et al. Among authors: baras as. Am J Cancer Res. 2015 Sep 15;5(10):2959-68. eCollection 2015. Am J Cancer Res. 2015. PMID: 26693052 Free PMC article.

7

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.

Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS, Miyamoto H. Kashiwagi E, et al. Among authors: baras as. Oncotarget. 2016 Aug 2;7(31):49169-49179. doi: 10.18632/oncotarget.9994. Oncotarget. 2016. PMID: 27322140 Free PMC article.

8

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.

Baras AS, Drake C, Liu JJ, Gandhi N, Kates M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, Netto G, Bivalacqua TJ. Baras AS, et al. Oncoimmunology. 2016 Feb 18;5(5):e1134412. doi: 10.1080/2162402X.2015.1134412. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467953 Free PMC article.

9

Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?

Brant A, Kates M, Chappidi MR, Patel HD, Sopko NA, Netto GJ, Baras AS, Hahn NM, Pierorazio PM, Bivalacqua TJ. Brant A, et al. Among authors: baras as. Urol Oncol. 2017 Jan;35(1):34.e17-34.e25. doi: 10.1016/j.urolonc.2016.08.005. Epub 2016 Sep 14. Urol Oncol. 2017. PMID: 27639777

10

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.

Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. Hahn NM, et al. Clin Cancer Res. 2017 Jun 15;23(12):3003-3011. doi: 10.1158/1078-0432.CCR-16-2267. Epub 2016 Dec 8. Clin Cancer Res. 2017. PMID: 27932416 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page